ATE502631T1 - Verbindungen zur behandlung von stoffwechselstörungen - Google Patents

Verbindungen zur behandlung von stoffwechselstörungen

Info

Publication number
ATE502631T1
ATE502631T1 AT04781277T AT04781277T ATE502631T1 AT E502631 T1 ATE502631 T1 AT E502631T1 AT 04781277 T AT04781277 T AT 04781277T AT 04781277 T AT04781277 T AT 04781277T AT E502631 T1 ATE502631 T1 AT E502631T1
Authority
AT
Austria
Prior art keywords
compounds
treatment
metabolic disorders
agent
metabolic
Prior art date
Application number
AT04781277T
Other languages
English (en)
Inventor
Shalini Sharma
Borstel Reid Von
Kirvin Hodge
Original Assignee
Wellstat Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Therapeutics Corp filed Critical Wellstat Therapeutics Corp
Application granted granted Critical
Publication of ATE502631T1 publication Critical patent/ATE502631T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AT04781277T 2003-08-20 2004-08-16 Verbindungen zur behandlung von stoffwechselstörungen ATE502631T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49653303P 2003-08-20 2003-08-20
PCT/US2004/026561 WO2005018628A1 (en) 2003-08-20 2004-08-16 Compounds for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
ATE502631T1 true ATE502631T1 (de) 2011-04-15

Family

ID=34216015

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04781277T ATE502631T1 (de) 2003-08-20 2004-08-16 Verbindungen zur behandlung von stoffwechselstörungen

Country Status (19)

Country Link
US (1) US7906675B2 (de)
EP (1) EP1656127B1 (de)
JP (1) JP4703563B2 (de)
KR (1) KR101069276B1 (de)
CN (2) CN1835743A (de)
AT (1) ATE502631T1 (de)
AU (1) AU2004266673B2 (de)
BR (1) BRPI0413758A (de)
CA (1) CA2533890A1 (de)
DE (1) DE602004031954D1 (de)
HK (1) HK1087040A1 (de)
IL (1) IL173377A (de)
MX (1) MXPA06001963A (de)
NO (1) NO20060502L (de)
NZ (1) NZ545268A (de)
RU (1) RU2349584C2 (de)
UA (1) UA88772C2 (de)
WO (1) WO2005018628A1 (de)
ZA (1) ZA200600577B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7615575B2 (en) * 2003-02-13 2009-11-10 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
SI1633340T1 (sl) * 2003-04-15 2011-02-28 Wellstat Therapeutics Corp Spojine za zdravljenje metaboličnih motenj
WO2004098496A2 (en) * 2003-04-30 2004-11-18 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US8022249B2 (en) * 2005-04-01 2011-09-20 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
UA95613C2 (ru) * 2005-11-09 2011-08-25 Уеллстат Терепьютикс Корпорейшн Соединения для лечения расстройсв метаболизма
US7947735B2 (en) * 2006-01-25 2011-05-24 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CA2637373A1 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CA2637375A1 (en) * 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
KR20080097418A (ko) * 2006-02-02 2008-11-05 웰스태트 테러퓨틱스 코포레이션 물질대사 장애의 치료용 화합물
CA2637884A1 (en) * 2006-02-13 2007-08-23 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
KR20080098615A (ko) * 2006-02-28 2008-11-11 웰스태트 테러퓨틱스 코포레이션 물질대사 장애의 치료용 화합물
AU2007235145B2 (en) * 2006-03-31 2011-09-22 Wellstat Therapeutics Corporation Combination treatment of metabolic disorders
CN101437506A (zh) * 2006-05-18 2009-05-20 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
MX2008015640A (es) * 2006-06-09 2009-01-09 Wellstat Therapeutics Corp Compuestos para el tratamiento de trastornos metabolicos.
EP2240024A4 (de) * 2008-01-15 2014-05-21 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
CN109096350B (zh) * 2017-09-21 2020-07-28 暨南大学 辣木籽中新的硫醚类化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5035M (de) 1964-07-28 1967-05-02
MXPA03011558A (es) * 2001-06-12 2004-03-26 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
US7645772B2 (en) * 2002-11-01 2010-01-12 Wellstat Therapeutics Corporation Treatment of metabolic disorders
US7615575B2 (en) * 2003-02-13 2009-11-10 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
SI1633340T1 (sl) * 2003-04-15 2011-02-28 Wellstat Therapeutics Corp Spojine za zdravljenje metaboličnih motenj
JP4697973B2 (ja) * 2003-04-22 2011-06-08 ウェルスタット セラピューティクス コーポレイション 代謝障害の処置のための化合物
WO2004098496A2 (en) * 2003-04-30 2004-11-18 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders

Also Published As

Publication number Publication date
AU2004266673B2 (en) 2010-08-05
RU2349584C2 (ru) 2009-03-20
IL173377A0 (en) 2006-06-11
UA88772C2 (ru) 2009-11-25
MXPA06001963A (es) 2006-05-31
ZA200600577B (en) 2007-01-31
KR20060066730A (ko) 2006-06-16
US20070282003A1 (en) 2007-12-06
JP2007502824A (ja) 2007-02-15
CN1835743A (zh) 2006-09-20
DE602004031954D1 (de) 2011-05-05
NZ545268A (en) 2009-05-31
EP1656127B1 (de) 2011-03-23
CA2533890A1 (en) 2005-03-03
RU2006108572A (ru) 2006-07-27
NO20060502L (no) 2006-05-03
WO2005018628A1 (en) 2005-03-03
BRPI0413758A (pt) 2006-10-31
US7906675B2 (en) 2011-03-15
KR101069276B1 (ko) 2011-10-04
CN101948416A (zh) 2011-01-19
IL173377A (en) 2012-12-31
EP1656127A4 (de) 2009-04-29
AU2004266673A1 (en) 2005-03-03
EP1656127A1 (de) 2006-05-17
JP4703563B2 (ja) 2011-06-15
HK1087040A1 (en) 2006-10-06

Similar Documents

Publication Publication Date Title
IL173377A0 (en) Compounds for the treatment of metabolic disorders
ATE402180T1 (de) Verbindungen zur behandlung von dyslipidemie
ATE368031T1 (de) Neue gamma secretase inhibitoren
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
NO20070606L (no) Inhibitorer av IAP
CY1106958T1 (el) Ν-αλκυλο-4-μεθυλεναμινο-3-υδροξυ-2-πυριδονες ως αντιμικροβιακα
ATE525067T1 (de) Amino-substituierte (e)-2,6-dialkoxystyryl 4- substituierte benzylsulfone zur behandlung von proliferierenden erkrankungen
DE602005009209D1 (de) Zur behandlung von entzündungen geeignete indole
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
TW200510317A (en) Caspase inhibitors and uses thereof
ATE338461T1 (de) Pyrazolpyrimidinfungizide
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
NO331012B1 (no) N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
DE60220385D1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
DE60327432D1 (de) Nützliche verbindungen für die behandlung von anthrax und hemmung des letalen faktors
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
SE0101082D0 (sv) Novel use
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
ATE539756T1 (de) Prostaglandinsubstanzen für die behandlung von fettsucht
NO20053562L (no) Nye aminobenzofenonforbindelser
ATE370733T1 (de) Pharmazeutische kombinationspräparat zur behandlung von spastischkeit und/oder schmerzen
GEP20084343B (en) Use of indole derivatives for the treatment of neuropathic pain

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties